TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company’s Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Our lead program TRB-061, currently in a Ph1 clinical trial for atopic dermatitis, is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California. For more info, visit www.trex.bio.
| Website | http://www.trex.bio |
| Employees | 61 (54 on RocketReach) |
| Founded | 2018 |
| Address | 681 Gateway Blvd 4th Floor, South San Francisco, California 94080, US |
| Technologies | |
| Industry | Biotechnology Research, Biotechnology |
| Keywords | Drug Development, Biotechnology, Biopharma, Therapeutics, Cancer Treatment, Life Sciences, Immunology, Drug Discovery, Computational Biology, Inflammatory Diseases, Human Tissue, Precision Medicine, Biomarker Discovery, Pharmaceutical Research, Molecular Biology, Clinical Trials, Genome Sequencing, Immunotherapy, Cell Therapy, Gene Editing |
| Competitors | Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, Sartorius, Promega Corporation, abcam, GenScript, Cell Signaling Technology (CST), LumiraDx, Pall ForteBio LLC +38 more (view full list) |
Looking for a particular TRexBio employee's phone or email?
Johnston Erwin is the CEO of TRexBio.
54 people are employed at TRexBio.
TRexBio is based in South San Francisco, California.